Before beginning any human gezegde

 Before beginning any human trials, the sponsor must perform extensive animal toxicity studies. Animal studies provide guidance on initial dosing and point to areas of safety needing special attention during human studies.

 Studies such as the one by Mangano and colleagues point the way to the prospective design of studies to assess drug safety and to the collection of as much information as necessary to provide answers of the highest quality.

 The large number of safety studies indicates that this issue has received a great amount of attention. Unfortunately, many of these studies involve more advocacy than science. It's not that these studies aren't valuable, but they have problems with methodology, statistical analysis and even simple understanding of important terms, such as 'speeding.' In accident data, speeding is defined as both 'traveling faster than the posted limit' and 'traveling too fast for conditions.' Studies often do not differentiate between these definitions.

 In our studies of HIV patients with painful feet -peripheral neuropathy- animal studies have already demonstrated that marijuana, where opioids don't work, works for nerve pain.

 I want to emphasize that human and animal health in the United States are protected by a system of interlocking safeguards, and that we remain very confident in the safety of U.S. beef. Again, this animal did not enter the human food or animal feed chains.

 Phase 2 studies are typically well controlled and closely monitored and may involve up to several hundred patients. At the conclusion of these studies, FDA (Food and Drug Administration) and the sponsor usually meet to determine how the drug's development should be studied in Phase 3 and how to design and conduct further trials.

 This early work is very encouraging, and we need to move forward with more research in animal models, and we need to move ahead with planning human studies.

 I'm really enthusiastic about the colleagues that I'll gain in [history and American studies], and film studies, gender and lesbian and gay studies, and around the University. And then, of course, there are amazing students at Yale, and I look forward to working with them.

 The great majority of post-marketing studies address safety issues, at least in part, so patients and physicians are denied critical safety information when these studies are not completed in a timely fashion.

 We have over 50 studies, and there is no clear-cut answer, ... We have positive studies. We have negative studies. I think the state of the art was beautifully illustrated in 1995 when we had reports from (two) respected teams of epidemiologists with opposite conclusions, two weeks apart.

 They haven't cleaned up the animal problem yet. We depend upon our country office, which investigates all these, and so far they have not given us any indication there is human-to-human transmission. It's just more of the same animal-human exposure.

 These events were completely unexpected and do not reflect the results we obtained from initial laboratory studies, which enabled us to progress investigations into human volunteers.

 The underlying problem is that the FDA has little ability to enforce these commitments, short of withdrawing approval for the drug - an outcome that may not serve the public health well. The great majority of post-marketing studies address safety issues, at least in part, so patients and physicians are denied critical safety information when these studies are not completed in a timely fashion.

 The underlying problem is that the FDA has little ability to enforce these commitments, short of withdrawing approval for the drug -- an outcome that may not serve the public health well. The great majority of post-marketing studies address safety issues, at least in part, so patients and physicians are denied critical safety information when these studies are not completed in a timely fashion.

 The underlying problem is that the FDA has little ability to enforce these commitments, short of withdrawing approval for the drug — an outcome that may not serve the public health well. The great majority of post-marketing studies address safety issues, at least in part, so patients and physicians are denied critical safety information when these studies are not completed in a timely fashion.


Aantal gezegden is 1469558
varav 1407627 på engelska

Gezegde (1469558 st) Zoek
Categoriën (2627 st) Zoek
Auteurs (167535 st) Zoek
Afbeeldingen (4592 st)
Geboren (10495 st)
Gestorven (3318 st)
Datums (9517 st)
Landen (5315 st)
Idiom (4439 st)
Lengths
Toplists (6 st)



in

Denna sidan visar ordspråk som liknar "Before beginning any human trials, the sponsor must perform extensive animal toxicity studies. Animal studies provide guidance on initial dosing and point to areas of safety needing special attention during human studies.".


Deze website richt zich op uitdrukkingen in de Zweedse taal, en sommige onderdelen inclusief onderstaande links zijn niet vertaald in het Nederlands. Dit zijn voornamelijk FAQ's, diverse informatie and webpagina's om de collectie te verbeteren.


Här har vi samlat ordstäv och talesätt i 35 år!

Vad är gezegde?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!



Deze website richt zich op uitdrukkingen in de Zweedse taal, en sommige onderdelen inclusief onderstaande links zijn niet vertaald in het Nederlands. Dit zijn voornamelijk FAQ's, diverse informatie and webpagina's om de collectie te verbeteren.


Här har vi samlat ordstäv och talesätt i 35 år!

Vad är gezegde?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!